Muromonab-CD3 (brand name Orthoclone OKT3, marketed by Janssen-Cilag) is an immunosuppressant medication given to reduce acute rejection in people with organ transplants. [1] [2] It is a monoclonal antibody targeted at the CD3 receptor, [3] a membrane protein on the surface of T cells.

The selective removal of CD3 by internalization is thought to be the key mechanism of action of OKT3. Comodulation of the antigen receptor with CD3 explains the immunoblocking action of OKT3 in vivo. Experience with a second or third treatment with OKT3 indicates that OKT3 is ineffective clinically if the CD3 target molecule is not modulated.

CD3, also known as T3, is a member of the immunoglobulin superfamily that plays a role in antigen recognition, signal transduction, and T cell activation. Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide. The antibody was purified by affinity chromatography.

Muromonab-CD3, also known as OKT3 (Orthoclone OKT3 ®), was the first monoclonal antibody approved for use in the United States. OKT3 targets the CD3 receptor found exclusively on mature T lymphocytes. The antibody is a murine-derived antibody that causes complete and rapid T-lymphocyte lysis and depletion.

Muromonab CD-3 (OKT-3) is a monoclonal antibody that is highly effective in the treatment of acute rejection in solid organ transplants. Due to its monoclonal nature, each molecule is identical because it is derived from a single antibody-producing clone. OKT-3 is administered only by intravenous in …

Description: The OKT3 monoclonal antibody reacts with an epitope on the epsilon-subunit within the human CD3 complex. The OKT3 antibody has been reported to have potent immunosuppressive properties in vivo and has been proven effective in the treatment of renal, heart and liver allograft rejection.

cd3分子是由肽链以 非共价键 组成的复合分子，在成熟t细胞表面表达，对阻断急性同种异体排斥反应起主要作用。 CD3分子与TCR组成复合受体分子，激活酪氨酸激酶，促使CD3分子 免疫受体酪氨酸活化基序 中的酪氨酸（Y）磷酸化。

Description: The OKT3 monoclonal antibody reacts with an epitope on the epsilon-subunit within the human CD3 complex. The OKT3 antibody has been reported to have potent immunosuppressive properties in vivo and has been proven effective in the treatment of renal, heart and liver allograft rejection.

The CD3 antibody recognizes the human CD3 antigen which is present on mature human T cells, thymocytes, and NKT cells. The epitope recognized by the antibody is located on the ε-chain of the CD3 complex. Clone OKT3 has been shown to activate T cell function.

okt3 是一种抗 cd3 mab，可在体内消耗 t 细胞，是急性同种异体移植排斥反应最有效的抑制剂之一。 这种抑制的机制是未知的。 目前的研究调查了抗 CD3 抗体是否具有交联两种不同细胞上的 CD3 并诱导 T 细胞之间的 TCR 依赖性抗体桥接细胞介导的细胞溶解 (TCR-ABCMC) 的 ...